Nucala - supply shortage

Resolved

mepolizumab

Shortage information

The shortage affecting Nucala has been resolved and the information and recommendations which were issued during the shortage no longer apply.

Key facts

• Medicines affected:
  Nucala
• Supply shortage status:
  Resolved
• International non-proprietary name (INN) or common name:
  mepolizumab
• Therapeutic area (MESH):
  Asthma
• Pharmaceutical forms affected:
  Pre-filled pen
• Strengths affected:
  • 40 mg
  • 100 mg
• Availability of alternatives:
  Yes

Key dates

• First published:
  28/01/2021
• Last updated:
  01/03/2021